Faculty Summaries
Lori J Goldstein, MD
Lori J. Goldstein, MD, FASCO
Professor
  • Director, Breast Evaluation Center

Recent Publications

  • Finn RS, Bengala C, Ibrahim N, Strauss LC, Fairchild J, Sy O, Roche H, Sparano J, Goldstein LJ. Phase II trial of dasatinib in triple-negative breast cancer: results of study CA 180059. Cancer Res. 2009;69(2):237S-237S.
  • Goldstein LJ, Sparano JA. Twenty-One-Gene Assay: Challenges and Promises in Translating Personal Genomics and Whole-Genome Scans Into Personalized Treatment of Breast Cancer REPLY. J Clin Oncol. 2009 Mar;27(8):1338-9.
  • Turaka A, Freedman GM, Li T, Anderson PR, Swaby R, Nicolaou N, Goldstein L, Sigurdson ER, Bleicher RJ. Young age is not associated with increased local recurrence for DCIS treated by breast-conserving surgery and radiation. J Surg Oncol. 2009 Jul 1;100(1):25-31.
  • Freedman GM, Anderson P, Litwin S, Swaby R, Nicolaou N, Sigurdson E, Ma C, Watkins-Bruner D, Morrow M, Goldstein L. Five-year Results of a Phase II Study of Hypofractionated IMRT with an Incorporated Boost for Breast Cancer. International Journal of Radiation Oncology Biology Physics. 2009;75(3):S77-S77.
  • Swaby RF, Wang M, Sparano JA, Bhalla K, Meropol NJ, Falkson CI, Pellegrino CM, Klein P, Goldstein LJ, Sledge GW. A Phase II Study of the Histone Deacetylase Inhibitor, Vorinostat, in Combination with Trastuzumab in Patients with Advanced Metastatic and/or Local Chest Wall Recurrent HER-2 Amplified Breast Cancer Resistant to Transtuzumab-Containing Therapy: (E1104) a Trial of the Eastern Cooperative Oncology Group. Cancer Res. 2009 Dec;69(24):793S-793S.
  • Goldstein LJ. Experience in Phase I Trials and an Upcoming Phase II Study with uPA Inhibitors in Metastatic Breast Cancer. 2008;:25-8.
  • Badve SS, Baehner FL, Gray RP, Childs BH, Maddala T, Liu ML, Rowley SC, Shak S, Perez EA, Shulman LJ, Martino S, Davidson NE, Sledge GW, Goldstein LJ, Sparano JA. Estrogen- and progesterone-receptor status in ECOG 2197: comparison of immunohistochemistry by local and central laboratories and quantitative reverse transcription polymerase chain reaction by central laboratory. J Clin Oncol. 2008 May 20;26(15):2473-81.
  • Carlson RW, Moench S, Hurria A, Balducci L, Burstein HJ, Goldstein LJ, Gradishar WJ, Hughes KS, Jahanzeb M, Lichtman SM, Marks LB, McClure JS, McCormick B, Nabell LM, Pierce LJ, Smith ML, Topham NS, Traina TA, Ward JH, Winer EP. NCCN Task Force Report: breast cancer in the older woman. J Natl Compr Canc Netw. 2008;6 Suppl 4:S1-S25; quiz S26-S27.
  • Chu QS, Cianfrocca ME, Goldstein LJ, Gale M, Murray N, Loftiss J, Arya N, Koch KM, Pandite L, Fleming RA, Paul E, Rowinsky EK. A phase I and pharmacokinetic study of lapatinib in combination with letrozole in patients with advanced cancer. Clin Cancer Res. 2008 Jul;14(14):4484-90.
  • Turaka A, Freedman G, Li T, Bleicher R, Swaby R, Nicolaou N, Goldstein L, Sigurdson E, Anderson P. Young age is not associated with increased local recurrence for DCIS treated by breast-conserving surgery and radiation. International Journal of Radiation Oncology Biology Physics. 2008;72(1):S151-S152.
  • Goldstein LJ, Gray R, Badve S, Childs BH, Yoshizawa C, Rowley S, Shak S, Baehner FL, Ravdin PM, Davidson NE, Sledge GW, Perez EA, Shulman LN, Martino S, Sparano JA. Prognostic utility of the 21-gene assay in hormone receptor-positive operable breast cancer compared with classical clinicopathologic features. J Clin Oncol. 2008 Sep 1;26(25):4063-71.
  • Goldstein LJ, O'Neill A, Sparano JA, Perez EA, Shulman LN, Martino S, Davidson NE. Concurrent doxorubicin plus docetaxel is not more effective than concurrent doxorubicin plus cyclophosphamide in operable breast cancer with 0 to 3 positive axillary nodes: North American Breast Cancer Intergroup Trial E 2197. J Clin Oncol. 2008 Sep 1;26(25):4092-9.
  • Borghaei H, Katherine Alpaugh R, Bernardo P, Palazzo IE, Dutcher JP, Venkatraj U, Wood WC, Goldstein L, Weiner LM. Induction of Adaptive Anti-HER2/neu Immune Responses in a Phase 1B/2 Trial of 2B1 Bispecific Murine Monoclonal Antibody in Metastatic Breast Cancer (E3194): A Trial Coordinated by the Eastern Cooperative Oncology Group. J Immunother. 2007 May/June;30(4):455-67.
  • O'Grady MA, Gitelson E, Swaby RF, Goldstein LJ, Sein E, Keeley P, Miller B, Li T, Weinstein A, Cohen SJ. Development and implementation of a medical oncology quality improvement tool for a regional community oncology network: the fox chase cancer center partners initiative. J Natl Compr Canc Netw. 2007 Oct;5(9):875-82.
  • Hayes DF, Thor AD, Dressler LG, Weaver D, Edgerton S, Cowan D, Broadwater G, Goldstein LJ, Martino S, Ingle JN, Henderson IC, Norton L, Winer EP, Hudis CA, Ellis MJ, Berry DA. HER2 and response to paclitaxel in node-positive breast cancer. N Engl J Med. 2007 Oct;357(15):1496-506.
  • Abramowitz MC, Li T, Nicolaou N, Anderson P, Goldstein L, Morrow M, Freedman G. Smoking does not affect the clinical presentation of breast cancer. International Journal of Radiation Oncology Biology Physics. 2007;69(3):S228-S228.
  • Freedman GM, Anderson PR, Goldstein LJ, Ma CM, Li J, Swaby RF, Litwin S, Watkins-Bruner D, Sigurdson ER, Morrow M. Four-week course of radiation for breast cancer using hypofractionated intensity modulated radiation therapy with an incorporated boost. Int J Radiat Oncol Biol Phys. 2007 Mar 20;68(2):347-53.
  • Carlson RW, O'Neill AM, Goldstein LJ, Sikic BI, Abramson N, Stewart JA, Davidson NE, Wood WC. A pilot phase II trial of valspodar modulation of multidrug resistance to paclitaxel in the treatment of metastatic carcinoma of the breast (E1195): A trial of the eastern cooperative oncology group. Cancer Invest. 2006 Nov;24(7):677-81.
  • Morrow M, Goldstein L. Surgery of the primary tumor in metastatic breast cancer: closing the barn door after the horse has bolted?. J Clin Oncol. 2006 Jun 20;24(18):2694-6.
  • Berry DA, Cirrincione C, Henderson IC, Citron ML, Budman DR, Goldstein LJ, Martino S, Perez EA, Muss HB, Norton L, Hudis C, Winer EP. Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION. 2006 Apr;295(14):1658-67.
  • Hayes DF, Thor A, Dressler L, Weaver D, Broadwater G, Goldstein L, Martino S, Ingle J, Henderson IC, Berry D. HER2 predicts benefit from adjuvant paclitaxel after AC in node-positive breast cancer: CALGB 9344. J Clin Oncol. 2006 Jun;24(18):5S-5S.
  • Manne SL, Ostroff JS, Norton TR, Fox K, Goldstein L, Grana G. Cancer-related relationship communication in couples coping with early stage breast cancer. Psychooncology. 2006 Mar;15(3):234-47.
  • Manne SL, Ostroff JS, Norton TR, Fox K, Grana G, Goldstein L. Cancer-specific self-efficacy and psychosocial and functional adaptation to early stage breast cancer. Ann Behav Med. 2006 Apr;31(2):145-54.
  • Freedman GM, Anderson P, Goldstein L, Litwin S, Li J, Watkins-Bruner D, Nicolaou N, Swaby R, Sigurdson E, Morrow M. A phase II study of four-week radiation for breast cancer using hypofractionated intensity modulated radiation therapy (IMRT) with an incorporated boost. International Journal of Radiation Oncology Biology Physics. 2006;66(3):S176-S176.
  • Freedman GM, Anderson P, Li TY, Ross E, Swaby R, Goldstein L. Identifying breast cancer patients most likely to benefit from aromatase inhibitor therapy after adjuvant radiation and tamoxifen. Cancer. 2006 Dec;107(11):2552-8.
  • Goldstein LJ. Controversies in adjuvant endocrine treatment of premenopausal women. Clinical Breast Cancer. 2006 Feb;6 Suppl 2:S36-40.
  • Chu Q, Goldstein L, Murray N, Rowinsky E, Cianfrocca M, Gale M, Ho P, Paul E, Loftiss J, Pandite L. A phase I, open-label study of the safety, tolerability and pharmacokinetics of lapatinib (GW572016) in combination with letrozole in cancer patients. J Clin Oncol. 2005 Part 1 Suppl. S JUN 1;23(16):192S-192S.
  • Chu Q, Rowinsky E, Goldstein L, Cianfrocca M, Murray N, Gale M, Ho PT, Loftiss JI, Paul E, Pandite L. Phase I study of lapatinib (GW572016) in combination with letrozole in cancer patients. EJC Supplements. 2005 Oct;3(2):119.
  • Freedman GM, Anderson P, Li T, Ross E, Swaby R, Goldstein L. Selection of breast cancer patients for an aromatase inhibitor after radiation and tamoxifen. International Journal of Radiation Oncology Biology Physics. 2005 2019 Suppl. 1;63(2):S242-S242.
  • Goldstein LJ, Cohen RB, Swaby R, Gallo JM, Bartz R, Muehlenweg B, Bevan P, Wilhelm OG. Antiproteolytic therapy targeting urokinase-plasminogen activator for the treatment of breast cancer - a phase I study. Clin Cancer Res. 2005 Part;11(24):9060S-9061S.
  • Gurtle JS, Goldstein L, Delprete S, Tjulandin S, Semiglazov V, Sternas L, Michiels B, Gilles E. Trabectedin in third line breast cancer: A multicenter, randomized, phase II study comparing two administration regimens. J Clin Oncol. 2005 Part 1 Suppl. S JUN 1;23(16):34S-34S.
  • Goldstein LJ, O'Neill A, Sparano J, Perez E, Shulman L, Martino S, Davidson N. E2197: Phase III AT (doxorubicin/docetaxel) vs. AC (doxorubicin/cyclophosphamide) in the adjuvant treatment of node positive and high risk node negative breast cancer. J Clin Oncol. 2005 Part 1 Suppl. S JUN 1;23(16):7S-7S.